Formycon AG completes clinical development of FYB206 in July 2026
Formycon AG announced that the clinical development of its biosimilar FYB206 was successfully completed in July 2026. The company also published the scientific foundation of the development program in the journal Biodrugs. FYB206 demonstrated pharmacokinetic equivalence to Keytruda in the pivotal Dahlia study.